Spotlight on reticular pseudodrusen

Abstract: Age-related macular degeneration (AMD) is a leading cause of vision loss in patients >50 years old. The hallmark of the disease is represented by the accumulation of extracellular material between retinal pigment epithelium and the inner collagenous layer of Bruch’s membrane, called drusen. Although identified almost 30 years ago, reticular pseudodrusen (RPD) have been recently recognized as a distinctive phenotype. Unlike drusen, they are located in the subretinal space. RPD are strongly associated with late AMD, especially geographic atrophy, type 2 and 3 choroidal neovascularization, which, in turn, are less common in typical AMD. RPD identification is not straightforward at fundus examination, and their identification should employ at least 2 different imaging modalities. In this narrative review, we embrace all aspects of RPD, including history, epidemiology, histology, imaging, functional test, natural history and therapy.

Keywords: age-related macular degeneration, choroidal neovascularization, geographic atrophy, reticular macular degeneration, reticular drusen, reticular macular disease, reticular pseudodrusen, subretinal drusenoid deposit

Introduction
Age-related macular degeneration (AMD) is a chronic, progressive degenerative retinal disease characterized by loss of central vision and represents one of the leading causes of blindness in subjects >50 years old.1 Being a distinctive feature of AMD, drusen appear on fundus examination as focal yellowish dots clustered at the posterior pole and are constituted by extracellular material accumulation between retinal pigment epithelium (RPE) and the inner collagenous layer of Bruch’s membrane (BM).1 In recent times, a distinctive phenotype, called reticular pseudodrusen (RPD), has been in the spotlight.

Here, we aim to provide the reader a comprehensive narrative review embracing all aspects of RPD.

Literature search
A PubMed engine search was carried out using the terms “reticular pseudodrusen”, “reticular drusen”, “subretinal drusenoid deposits”, and “reticular macular disease”. All studies published in English up to July 2017, irrespective of their publication status, were reviewed and relevant publications were included in this review.

History
Mimoun et al2 described for the first time “pseudodrusen visible en lumière bleue” in 1990 to define retinal lesions with a variable diameter of about 100 μm that did not appear hyperfluorescent on fluorescein angiography (FA), but with enhanced visibility in blue light. In 1991, RPD were incorporated into the Wisconsin AMD grading system.
as “ill-defined networks of broad interlacing ribbons” on color fundus photography and were named reticular soft drusen. In 1995, Arnold et al further characterized RPD as “yellow interlacing network 125–250 μm wide appearing first in the superior outer macula and then extending circumferentially and beyond” and coined the terminology RPD. Since then, the nomenclature RPD spread in the current literature, although other terms (ie, subretinal drusenoid deposits, reticular macular disease, reticular drusen) have been used.

### Epidemiology

#### Prevalence

Prevalence of RPD varies in relation to the modality of evaluation and the cohort of patients enrolled. Prevalence of RPD in general elder population was assessed by large, long-term follow-up prospective studies, namely, Beaver Dam Eye, Blue Mountains Eye and Melbourne Collaborative Cohort studies. In those studies, the prevalence of RPD turned to be 0.41%–1.95% and 3.0%–4.0% at baseline and 15 years, respectively. However, the sensitivity of color fundus photography is very low. Conversely, novel imaging modalities (ie, spectral-domain optical coherence tomography [SD-OCT], infrared [IR] reflectivity and multicolor) exhibited excellent sensitivity/specificity, and, therefore, studies employing these modalities disclosed higher prevalence of RPD. In the Rotterdam Eye Study, RPD were detected in about 5% of participants using color fundus photograph (CFP) and near-infrared reflectance (NIR). Prevalence of RPD was even higher ranging from 13.4% to 32% when multimodal imaging was employed. Interestingly, RPD seem to be less frequent in Asiatic compared with White populations. RPD are bilateral in 50%–84% of cases.

Independently from the macular status, the presence of RPD in older population increased 3.4-fold the chance to suffer from AMD in general elder population. Prevalence of RPD in patients with AMD is obviously higher than that in general population, ranging from 16.8% to 79%, depending on the imaging modality used, stage and type of AMD. Surprisingly, RPD prevalence was even higher (85%) in postmortem histological samples of patients with AMD. Although their overall presence in neovascular AMD ranges between 22% and 36%, RPD are more easily found in eyes with type 3 neovascularization (CNV) (68.4%–83%). Conversely, they are less commonly seen in eyes with typical neovascular AMD (type 1 and 2) or polypoidal choroidal vasculopathy with a prevalence of 9%–13.9% and 2%–3.4%, respectively. In eyes with geographic atrophy, the prevalence of RPD ranges between 29% and 50%. An association between RPD and acquired vitelliform detachment has been reported, suggesting RPE dysfunction and impairment to outer segments turnover.

Although RPD are commonly found in AMD, they have also been associated with other retinal affections, including early-onset drusen, pseudoxanthoma elasticum, Sorsby macular dystrophy, and adult-onset foveomacular vitelliform dystrophy. RPD have been anecdotally reported in late-onset macular degeneration, vitamin A deficiency and IgA nephropathy.

### Risk factors

RPD occur in the setting of AMD, and, therefore, phenotypic features of AMD are associated with higher risk of RPD presence. Patients with late AMD have the highest odds of having RPD, and the risk is greater in the geographic atrophy (GA) over the CNV phenotype, followed by intermediate and early stages. Large druse and focal pigmentary changes are additional risk factors for RPD presence. AMD and RPD share several non-ocular risk factors, including older age, female sex, current smoking and high body mass index. Other reported risk factors for RPD include less education, B-vitamin complex use, history of steroid eye drop use and glaucoma. As for AMD, the prevalence of RPD is lower in patients with diabetes. In the Beaver Dam Eye Study, RPD were an independent risk factor for mortality, and Cymerman et al have recently reported higher prevalence of RPD in patients with coronary artery disease. Compared with AMD without RPD, patients with RPD demonstrated higher rates of systemic hypertension, angina and mortality. However, this association is still under debate, and other studies did not confirm association between RPD and cardiovascular risk factors. Decreased renal function represents another vascular association; interestingly, both choroid and kidney share a lobular, end-arterial vascular system, and this could account for this connection.

With the advent of the enhanced depth imaging (EDI-) and swept-source (SS)-OCT, several studies focused on the choroidal imaging. A reduction of the subfoveal choroidal thickness has been extensively demonstrated in patients with RPD when compared not only with healthy subjects but also with AMD without RPD. Also, choroidal thinning involves all the macula area and even areas outside the macula, such as in the peripapillary region, suggesting a widespread choroidal involvement. Employing choroidal binarization, Corvi et al showed that stromal area is more represented in patients suffering from AMD with RPD compared with those without RPD, suggesting a choroidal...
vascular depletion and fibrotic replacement. Zheng et al illustrated choroidal vessel density reduction in eyes with RPD, suggesting that RPD may be a sign of choroidal vasculopathy. Interestingly, areas of lowest vessel density did not correspond to the location of thinnest choroid, and, therefore, RPD may be related to a global choroidal dysfunction leading to choriocapillaris hypoperfusion, possibly indicating an ocular sign of systemic vascular deficiency.

Little is known regarding genetic susceptibility and RPD. Two major AMD risks alleles, namely, complement factor H (CHF, rs1061170) 402H on chromosome 1q32 and the age-related maculopathy susceptibility 2 (ARMS2, rs10490924) 69S on chromosome 10q26, have been pointed out by large studies. Data regarding RPD are controversial. The Beaver Eye Study and the Blue Mountain Eye Study revealed a linkage between RPD and both ARMS2 and CHF Y402H. Smith et al found ARMS2 and CHF 402H variant as a risk and protective factor, respectively. In the Melbourne Collaborative Cohort Study, the ARMS2 single-nucleotide polymorphism (SNP) rs10490924, HTRA1 SNPs rs11200638 and rs3793917, and CFH SNPs rs393955, rs1061170 and rs2274700 were linked to higher prevalence of RPD. Association between RPD and ARMS2 allele was also confirmed in Japanese population. Buitendijk et al found CFH, C2/FB and ARMS2 to be associated with both RPD and soft drusen, whereas C3 was linked only to RPD.

Conversely, Puche et al did not find any genotypic difference between AMD patients with and without RPD. Similarly, Boddu et al did not find any association between RPD and both ARMS2 and CHF alleles.

**Histology**

Different from drusen, which are made of lipids gathering in the BM (basal deposits), RPD are histologically characterized by the accumulation of material in the subretinal space extending up to the outer segment and even in the outer nuclear layers. Neighboring structures are affected by the presence of RPD, which is associated with RPE polymegathism, photoreceptor disruption and reactive gliosis.

Although RPD have some similarities with drusen in their composition (ie, neutral lipid, cholesterol, amyloid, complement factor, and membranous debris), they have significant differences in their components, and, therefore, RPD are not just drusen material located above the RPE. RPD have higher concentration of unesterified cholesterol, vitronectin, include opsins, peanut agglutinin, and photoreceptor pigments (including precursors of A2E/lipofuscin). Since RPD and drusen lipids did not stain with the same dye, differences in lipid composition have been postulated. Moreover, RPD are rich in immune cells, predominantly immune-reactive microglia and macrophages, confirming the role of inflammation. However, precise composition of RPD is yet to be determined.

**Imaging**

Different imaging modalities alone or in combination have been used to investigate RPD, including CFP, IR, short wavelength (SW)- and NIR-fundus autofluorescence (FAF), multicolor, OCT, en face OCT, OCT angiography (OCT-A), FA, indocyanine green angiography (ICGA) and adaptive optics. Figure 1 shows multimodal imaging of an eye with RPD. Written informed consent was received from all patients for publication of images in this review.

Multimodal imaging studies revealed that IR, FAF, SD-OCT and widefield en face SS-OCT have the highest sensitivity in detecting RPD, whereas late phases of ICGA, blue channel of CFP and confocal blue reflectance (CBR) have almost perfect specificity. However, there is no real gold standard for PRD detection, and use of at least 2 imaging modalities has been advocated. It has been suggested to use a high sensible modality (ie, SD-OCT, IR) as a screening test and a high specific one (ie, ICGA, CFP, CBR) as confirmation.

**Color fundus photograph**

CFP reveals RPD as yellowish, ill-defined network of broad, interlacing ribbons preferentially located in the superior aspect of the macular area, which tends to become more punctate as they become closer to the fovea. The blue channel of CFP allows better contrast of RPD since the SW of blue light is highly reflected by the RPD, but preferentially absorbed by melanin contained in the RPE surrounding the RPD, creating contrast. Although some milestone studies employed CFP to individuate RPD, the diagnostic ability of this technique is unsatisfactory, due to the low sensitivity. On the contrary, its specificity is extremely high, virtually reaching 100%, and, therefore, it could be a powerful confirmatory test.

**Fundus autofluorescence**

SW-FAF (excitation λ=488 nm; emission λ>500 nm) reveals RPD as hypofluorescent. The reason why RPD appear as hypofluorescent is still uncertain. One possible explanation is that the reflection and blockage of the blue excitation light prevent it from reaching the RPE.

On the other hand, most RPD deposits/subretinal materials may have an isofluorescent core conferring to these lesions a
This peculiar aspect could derive from the accumulation in the RPD core of lipofuscin-like material, probably representing unphagocytized photoreceptor outer segments; alternatively, it could be related to the interruption of ellipsoid zone (EZ). The absence of the target aspect in some RPD could be ascribed to heterogeneity in RPD composition or confocal selective laser ophthalmoscopy properties.

Interestingly, a small subset of patients may have intense hyperfluorescent RPD, which have been initially reported as less associated with late AMD, even though it was not confirmed by later analysis. It has been speculated that hyperfluorescent RPD could be a transient form of pseudodrusen or small foci of acquired vitelliform material. RPD extent increases over time, and it has been estimated to have a mean growth rate of 4.4 mm²/year. Using quantitative FAF (qFAF), it has been observed that eyes with RPD have lower qFAF values compared with patients with soft drusen, cuticular drusen and controls even in unaffected retina areas.
Reduced qFAF values could reflect reduction in (intracellular but not extracellular) lipofuscin accumulation due to dysfunction in choroid-BM-RPE complex, slowing in visual cycle, reduced cone and rod densities and different composition of lipofuscin.\textsuperscript{74} Since it is rapid, noninvasive, highly reliable, accurate (sensitivity: 86%, specificity: 92%–95%), SW-FAF is a valuable imaging modality to identify RPD.\textsuperscript{18,68,75} Conversely, NIR-FAF (excitation $\lambda=787$ nm; emission $\lambda>800$ nm) has not good diagnostic abilities.\textsuperscript{18}

**IR and multicolor**

RPD appearance at IR imaging parallels FAF showing a hyporeflective reticular pattern and a variable target aspect, with an isoreflective core surrounded by hyporeflective halo.\textsuperscript{24,35,73,76} Using multimodal imaging (including CFP, IR and OCT), Suzuki et al\textsuperscript{66} subclassified RPD in 3 different subtypes: dot, ribbon and midperipheral. In the first type, IR reveals perifoveal hyperreflective dots often showing a target aspect; the second type is characterized by perifoveal faint hyporeflective ribbons; and the third subtype is featured by midperipheral hyperreflective spots.\textsuperscript{66} Different RPD subtypes may have distinct components and may confer differing risk of disease progression.\textsuperscript{66} Since it is noninvasive, fast, high sensible and reliable, IR imaging has been advocated as a screening test to identify RPD.\textsuperscript{18}

MultiColor (Spectralis SD-OCT; Heidelberg Engineering, Heidelberg, Germany) merges 3 different laser channels (ie, IR: $\lambda=820$ nm; green reflectance: $\lambda=515$ nm; blue reflectance at $\lambda=488$ nm) into a single pseudocolor image. RPD have a peculiar yellowish-green reticular pattern and are more evident at green and IR than at blue reflectance.\textsuperscript{77} Similar to IR, RPD may have a target appearance with a more intense yellowish/greenish core surrounded by a decreased intensity.\textsuperscript{75,77} MultiColor demonstrated equal identification rates of FAF and IR and higher individuation of target aspect.\textsuperscript{75,76} The green–blue enhanced mode, which stresses blue and green channels, reveals RPD as green/gray lesions, but has lower detection rates than standard MultiColor, confirming the value of the IR component.\textsuperscript{75}

**OCT, en face OCT and OCT-A**

SD-OCT shows RPD as discrete accumulation of hyperreflective material above the RPE in the subretinal space.\textsuperscript{79,80} Although contradicted by some studies, it is widely accepted that that hyperreflective subretinal drusenoid material seen at SD-OCT corresponds to RPD seen at other imaging modalities.\textsuperscript{15,76,80,81} Zweifel et al\textsuperscript{80} cataloged RPD in 3 different stages: 1) diffuse accumulation of granular hyperreflective material between RPE and EZ, 2) mounds of material bowing and distorting EZ profile and 3) conical amassing with focal interruption of EZ. Subsequently, Querques et al\textsuperscript{80} elucidated that RPD are dynamic structures characterized by agglomeration of subretinal material; moreover, they illustrated that the drusenoid material eventually reabsorbs and migrates into the inner retinal layers, and this was referred to as stage 4. Auge et al\textsuperscript{82} confirmed the dynamism of RPD and emphasized the importance of dense scan protocols and exact registration of B-scans in the follow-up. Advanced stages of pseudodrusen life cycle are associated with sublesional RPE degeneration and shortening of photoreceptors.\textsuperscript{83} Small series reported that RPD can completely disappear during the time, and this phenomenon may be unilateral and asymmetric.\textsuperscript{84} RPD disappearance may leave outer retinal atrophy and focal reduction in choroidal thickness, and this could represent a novel phenotype of late AMD not included in the current classification systems.\textsuperscript{83} It has been speculated that outer retinal atrophy following RPD regression may eventually involve RPE and choriocapillaris, leading to GA.\textsuperscript{86}

As previously discussed, several studies using EDI- and SS-OCT demonstrated that eyes with RPD are characterized by choroidal vascular depletion and fibrotic replacement, resulting in a widespread reduction in choroidal thickness even in comparison with other AMD phenotypes.\textsuperscript{43–52} Mrejen and Spaide\textsuperscript{87} observed that RPD have low prevalence in eyes with very thin choroid (ie, pathologic myopia), and, therefore, they argued that RPD accumulation is unlikely to be related to a primary dysfunction at the choroidal level, but rather explained by other factors (eg, RPE dysfunction). However, this argument fails to consider that the thin choroid in high myopia can be functionally and structurally healthy, compatible with normal visual function. Interestingly, high prevalence of RPD has been reported in eyes suffering from age-related choroidal atrophy, which is an entity recently described characterized by choroidal thickness reduction, pigmentary changes and scarcity of visible choroidal vessels, reflecting a disease of small vessels involving the choroid.\textsuperscript{88} Using OCT-A (Figure 2), eyes with RPD exhibited a reduction in choriocapillary vessel density more extensive than in those with drusen and no RPD and which has been associated with poor visual acuity.\textsuperscript{89–91}
such as RPE, that are able to alter the polarization state of the light.\(^9\) PS-OCT can identify RPD, which preserve polarization, and distinguish them from drusen, which, conversely, alter polarization.\(^9\) However, PS-OCT has not broken into the clinical practice, and its diagnostic properties are still unknown.

In addition to RPD identification, some authors have tried to determine whether OCT could provide information on the natural history of the disease. RPD thickness was a robust biomarker of future areas of GA growth.\(^9\)\(^5\)\(^-\)\(^9\)\(^7\) Moreover, EZ disruption pattern has been related to GA progression over time.\(^9\)\(^8\) Identification of biomarkers and anatomic surrogates predicting future vision loss could be beneficial for clinical trials concerning early or intermediate AMD.\(^9\)\(^9\)

**FA and ICGA**

FA may reveal RPD as a filling defect in the choriocapillaris in early frames; however, due to its low sensitivity and invasive nature, it is seldom performed.\(^9\)\(^3\)

RPD are seen as hypofluorescent dots at mid and late phases of ICGA, which co-localize with dots seen at IR and FAF, suggesting a pathology internal to RPE.\(^1\)\(^4\)\(^1\)\(^0\)\(^1\) Using IR and ICGA, Querques et al\(^4\)\(^4\) showed that RPD co-localize with choroidal intervascular stroma with sparing of areas above large choroidal vessels, suggesting impaired choroidal filling. Similarly, Alten et al\(^1\)\(^0\)\(^1\) observed that RPD are located in areas of choroidal watershed, reinforcing the pathogenic role of choroidal hypoxia. However, further study did not find concordance between RPD and large choroidal blood vessels.\(^1\)\(^0\)\(^2\) Although it owns good diagnostic abilities (sensitivity: 73%, specificity: 100%), ICGA is not the first choice test because of its invasive nature.\(^1\)\(^8\) As shown in Figure 3, FA and ICGA have a pivotal role in diagnosing CNV associated with RPD.

**Adaptive optics**

By improving the transverse resolution to 2 μm, adaptive optics visualize cone photoreceptors in vivo. Adaptive optics illustrate RPD as isoreflective lesions surrounded by a continuous/discontinuous hyporeflective halo, with the hyporeflective core ascribed to the drusenoid material itself and the hyporeflective halo related to absent or degenerated photoreceptors correspondent to EZ disruption.\(^1\)\(^0\)\(^3\) Photoreceptors mosaic is perturbed by RPD according to lesion stage; specifically, stages 1 and 2 are characterized by a reduction in photoreceptor density, whereas only stage 3 has an annular
Figure 3 Multicolor imaging, FA, fundus autofluorescence, ICGA and structural SD-OCT of a patient affected by RPD and a type 1 CNV.

Notes: (A, D) Multicolor imaging (A) and fundus autofluorescence (D) showing RPD, a large hemorrhage around the central lesion. FA (B, C) and ICGA (E, F) revealing the presence of a type 1 CNV with a typical hyperfluorescent plaque in the late phase of ICGA (F). (G, H) Combined ICGA and structural horizontal and vertical SD-OCT B-scans passing through the fovea revealing the presence of RPD and an active type 1 CNV. Green arrows show the position of the scan lines used to generate the cross-sectional SD-OCT images.

Abbreviations: FA, fluorescein angiography; ICGA, indocyanine green angiography; SD-OCT, spectral-domain optical coherence tomography; RPD, reticular pseudodrusen; CNV, choroidal neovascularization.
configuration.\textsuperscript{104,105} As shown by OCT studies, dynamism of RPD was further confirmed using adaptive optics.\textsuperscript{106}

Mrejen et al\textsuperscript{117} showed that cone density over and around RPD is lower than drusen and healthy controls, suggesting that RPD could affect retinal function even in the absence of CNV or GA. On the contrary, Querques et al\textsuperscript{103} found that cone density similarly decreased in drusen and RPD.

### Functional tests

AMD is characterized by abnormal retinal function even in early or intermediate stage. Impairment in dark adaption and low-luminance visual acuity have been demonstrated in AMD, and these parameters are more severely affected by the presence of RPD potentially reflecting impairment in rod function.\textsuperscript{68,108,109} In agreement with this hypothesis, Steinberg et al\textsuperscript{110} illustrated a more pronounced deterioration of mean threshold sensitivity at scotopic than at photopic microperimetry. A recent study comparing eyes in normal macular health with and without RPD illustrated no significant difference regarding photopic acuity, mesopic acuity, low-luminance acuity, photopic contrast sensitivity and photopic light sensitivity.\textsuperscript{111} In the same study, eyes with RPD exhibited delayed dark adaptation, although significant differences in age between the 2 groups could be imputable for such a difference.\textsuperscript{111}

Eyes with RPD have reduction in microperimetric retinal sensitivity despite preserved visual acuity.\textsuperscript{112} Compared with drusen, RPD are associated with a more pronounced impairment in macular sensitivity.\textsuperscript{113} Whether the extent of RPD is related to macular sensitivity is still unclear and contrasting results have been published.\textsuperscript{114,115}

By recording local electoretinographic responses from the central 40°–50° of the macula, multifocal electoretinography (mfERG) allows assessing retinal function in a topographic way. Studies involving mfERG reported contrasting results.\textsuperscript{115–117} Alten et al\textsuperscript{116,117} did not find any significant difference between patients with RPD and healthy controls. Comparing areas with and without pseudodrusen, they observed no significant differences at baseline; conversely, reduction in amplitude was seen in affected areas during the follow-up, suggesting a progressive decline in retinal function over time, which did not correlate with structural data.\textsuperscript{116,117} Wu et al\textsuperscript{115} reported conflicting results, showing that RPD presence and extent in intermediate AMD are independently linked to worse mfERG implicit time, but not to amplitude.

### Natural history

As illustrated in the aforementioned paragraphs, RPD are dynamic structures evolving and even reabsorbing with time. RPD confer a higher risk of developing AMD during follow-up. In elder population with an otherwise healthy macula, RPD were found in the 25% of subjects conferring a 2-fold risk to develop early AMD.\textsuperscript{118} In addition, the presence of RPD increase is significantly associated with higher odds to progress to late AMD.\textsuperscript{6,119} In fellow eyes of patients with unilateral CNV, the presence of AMD conferred extra odds to progress to late AMD.\textsuperscript{112} RPD are linked to the development of GA, especially with multilobular type, and higher progression rates.\textsuperscript{96,97,120} RPD are a strong risk factor for developing type 3 CNV, and, moreover, they are associated with higher earlier onset and bilateral disease.\textsuperscript{110,122} Eyes affected by type 3 CNV have higher odds to have also RPD, and, for this reason, RPD have been advocated as a diagnostic sign to distinguish type 3 CNV from other forms.\textsuperscript{123,124} Eyes with exclusively RPD have been associated with type 2 CNV.\textsuperscript{125} In case of CNV development, RPD fade nearby the CNV itself, but they may still be observed more peripherally.\textsuperscript{14,69}

RPD are a risk factor to develop atrophy following intra-vitreal anti-vascular endothelial growth factor (VEGF).\textsuperscript{126–128} However, presence of RPD did not interfere with the response to intravitreal anti-VEGF, at least in the short term.\textsuperscript{129}

### Therapy

No specific therapy is available for RPD. Since RPD are in the spectrum of AMD, they can benefit from vitamin supplementation (ie, AREDS and AREDS2 formula) in case of early and intermediate diseases.\textsuperscript{130} Beyond reducing the risk of late AMD development, supplementation with macular pigment component (ie, lutein, zeaxanthin and meso-zeaxanthin) may increase the macular pigment optical density primarly, if not only, in the RPD phenotype.\textsuperscript{131} Presence of RPD in the setting of late AMD has no impact on the therapeutic strategy.

### Conclusions

RPD represent a specific component of AMD, although they may be found even in other ocular diseases. They differ from drusen not only for their location (ie, subretinal space) but also for their components. Their presence should always be sought in patients suffering from AMD, since they are strongly associated with late stages of disease. RPD identification should employ at least 2 different imaging modalities, since their recognition may not be straightforward with one technique only. Future clinical trials and epidemiological studies should take into account RPD phenotype employing imaging modalities suitable for their identification.

### Disclosure

GQ is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Bayer...
Schering-Pharma (Berlin, Germany), Heidelberg (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Zeiss (Dublin, OH, USA). FB has the following disclosures: Allergan (s), Alimera (s), Bayer (s), Farmila-Thea (s), Schering Pharma (s), Sanofi-Aventis (s), Novagali (s), Pharma (s), Hoffmann-La Roche (s), Genentech (s) and Novartis (s). The other authors report no conflicts of interest in this work.

References


